X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA AUROBINDO PHARMA AJANTA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 21.8 19.3 113.0% View Chart
P/BV x 5.1 4.8 105.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 AJANTA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-17
AJANTA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818895 203.1%   
Low Rs1,106622 177.8%   
Sales per share (Unadj.) Rs239.5254.6 94.1%  
Earnings per share (Unadj.) Rs52.839.3 134.4%  
Cash flow per share (Unadj.) Rs59.546.6 127.8%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs230.0160.0 143.8%  
Shares outstanding (eoy) m88.77585.88 15.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.13.0 204.9%   
Avg P/E ratio x27.719.3 143.4%  
P/CF ratio (eoy) x24.616.3 150.9%  
Price / Book Value ratio x6.44.7 134.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m129,782444,390 29.2%   
No. of employees `0006.814.0 48.6%   
Total wages/salary Rs m3,76517,678 21.3%   
Avg. sales/employee Rs Th3,128.410,667.8 29.3%   
Avg. wages/employee Rs Th554.01,264.3 43.8%   
Avg. net profit/employee Rs Th689.71,645.8 41.9%   
INCOME DATA
Net Sales Rs m21,258149,157 14.3%  
Other income Rs m2421,159 20.8%   
Total revenues Rs m21,499150,316 14.3%   
Gross profit Rs m6,58434,343 19.2%  
Depreciation Rs m5964,276 13.9%   
Interest Rs m4667 0.6%   
Profit before tax Rs m6,22630,558 20.4%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5397,597 20.3%   
Profit after tax Rs m4,68623,012 20.4%  
Gross profit margin %31.023.0 134.5%  
Effective tax rate %24.724.9 99.5%   
Net profit margin %22.015.4 142.9%  
BALANCE SHEET DATA
Current assets Rs m12,23692,062 13.3%   
Current liabilities Rs m3,46166,223 5.2%   
Net working cap to sales %41.317.3 238.3%  
Current ratio x3.51.4 254.4%  
Inventory Days Days60106 56.8%  
Debtors Days Days8468 124.8%  
Net fixed assets Rs m11,14062,919 17.7%   
Share capital Rs m177586 30.2%   
"Free" reserves Rs m20,23793,133 21.7%   
Net worth Rs m20,41493,719 21.8%   
Long term debt Rs m101,814 0.6%   
Total assets Rs m24,486162,494 15.1%  
Interest coverage x1,519.446.8 3,246.6%   
Debt to equity ratio x00 2.6%  
Sales to assets ratio x0.90.9 94.6%   
Return on assets %19.214.6 131.5%  
Return on equity %23.024.6 93.5%  
Return on capital %30.532.7 93.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66775,838 15.4%   
Fx outflow Rs m1,61630,224 5.3%   
Net fx Rs m10,05245,613 22.0%   
CASH FLOW
From Operations Rs m2,85432,786 8.7%  
From Investments Rs m-2,604-17,870 14.6%  
From Financial Activity Rs m-2-19,153 0.0%  
Net Cashflow Rs m248-4,239 -5.9%  

Share Holding

Indian Promoters % 73.8 54.1 136.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.0 19.5%  
FIIs % 7.6 27.7 27.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.2 166.7%  
Shareholders   20,968 69,601 30.1%  
Pledged promoter(s) holding % 4.4 8.6 51.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  MERCK LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS